Debu Tripathy, MD

Debu Tripathy, MD, discusses the TBCRC049 study which evaluated tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

Debu Tripathy, MD, discusses the use of CDK4/6 inhibitors for the treatment of HER2-negative breast cancer based on the results from the phase III MONALEESA-7 trial.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline <em>BRCA</em> 1/2 mutations during the 2017 ASCO Annual Meeting.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the link between circulating tumor cells and survival outcomes in metastatic breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the dilemma of managing a patient who has residual disease after receiving neoadjuvant therapy.

Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.

Debu Tripathy, MD, discusses the further investigation into immunotherapy's role in treating breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses using adjuvant bisphosphonates as a treatment option for patients with breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.

Debu Tripathy, MD, discusses targeting HER2 in breast cancer.

Debu Tripathy, MD, from the Norris Comprehensive Cancer Center, discusses the treatment of breast cancer with anthracyclines and trastuzumab.

Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.

Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses two important trials in breast cancer looking at extended hormonal therapy.